Rosetta to Debut Array-Based Cancer-of-Unknown-Primary Test in H2

CEO Kenneth Berlin said that the next-generation version of Rosetta's miRview Mets test will run on an array platform, and that the firm's CLIA lab was recently upgraded to include a microarray room to process the test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.